Table 3.
MedDRA SOC/Preferred term | Placebo (n = 24) | Varenicline (n = 23) | p |
---|---|---|---|
Nausea | 4 (16.7%) | 10 (43.5%) | 0.060 |
Abnormal dreams | 5 (20.8%) | 7 (30.4%) | 0.517 |
Nasopharyngitis | 6 (25.0%) | 1 (4.3%) | 0.097 |
Bright urine | 1 (4.2%) | 3 (13.0%) | 0.348 |
Note. Multiple occurrences of a specific adverse event for a participant were counted once in the frequency for the adverse event.